


Inflammation in asthma is heterogeneous and dynamic¹⁻⁴

Patients can have concurrent overlapping pathways, and their dominant pathway can change over time¹⁻⁴



In a study investigating phenotype stability by sputum analysis, ~50% of patients with severe asthma changed their biomarker profile after 1 year of follow up^{3,a}

The number of lines is a relative representation of the number of patients. EOS high: $\geq 2\%$; NEU high: $\geq 40\%$ in induced sputum³

^aPhenotype change (based on biomarkers) in full cohort (included patients with mild/moderate and severe asthma; n= 52)³

EOS = Eosinophils; NEU = Neutrophils

1. Busse WW. Allergol Int 2019;68:158–166; 2. Canonica GW. Oral presentation at WAC 2019 (Abstract OC35); 3. Kupczyk M, et al. Allergy 2014;69:1198–1204; 4. Tran TN et al. Ann Allergy Asthma Immunol 2016;116:37–42.